• FirefoxUpgrade to the new Firefox »
  •  Dow Up2.43% Nasdaq Up2.24%

    Biogen Idec Inc. (BIIB)

    -NasdaqGS
    353.70 Up 20.81(6.25%) 4:00PM EST
    |After Hours : 354.00 Up 0.30 (0.08%) 6:58PM EST - Nasdaq Real Time Price
    Add to Portfolio
    ProfileGet Profile for:
    Biogen Idec Inc.
    225 Binney Street
    Cambridge, MA 02142
    United States - Map
    Phone: 781-464-2000
    Website: http://www.biogenidec.com

    Details 
    Index Membership:N/A
    Sector:Healthcare
    Industry:Biotechnology
    Full Time Employees:6,850

    Business Summary 

    Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. It provides AVONEX to treat relapsing MS; TYSABRI to treat relapsing forms of MS and Crohn’s disease; RITUXAN for treating relapsed or refractory, follicular, CD20-positive, and B-cell Non-Hodgkin’s lymphoma (NHL); FUMADERM to treat severe plaque psoriasis in adult patients; FAMPYRA, an oral compound for the improvement of walking in adult patients with MS; TECFIDERA for the treatment of MS; and GAZYVA, an injection for intravenous infusion that treats an untreated chronic lymphocytic leukemia. The company’s products that completed Phase III clinical trials comprise ELOCTATE and ALPROLIX, an inherited disorder that inhibits blood coagulations; and Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company’s Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; Neublastin for neuropathic pain; and ANTI-TWAEK for lupus nephritis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; BIIB037 for MS; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial products include ISIS-SMNRx for spinal muscular atrophy. Biogen Idec Inc. has collaboration agreements with Genentech, Inc.; Acorda Therapeutics, Inc.; Sangamo BioSciences; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.

    Key Statistics


    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Biogen Idec Inc.

    Corporate Governance 
    Biogen Idec Inc.’s ISS Governance QuickScore as of Dec 1, 2014 is 2. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 2; Compensation: 3.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
     PayExercised
    Dr. George A. Scangos Ph.D., 66
    Chief Exec. Officer and Director
    5.73M0.00
    Mr. Paul J. Clancy , 52
    Chief Financial Officer and Exec. VP of Fin.
    1.65M23.27M
    Mr. Stuart A. Kingsley , 50
    Exec. VP of Global Commercial Operations
    1.47M0.00
    Mr. John G. Cox , 51
    Exec. VP of Pharmaceutical Operations & Technology
    1.42M0.00
    Dr. Douglas Edward Williams Ph.D., 56
    Exec. VP of R&D
    1.67M0.00
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders